Side-by-side · Research reference
EpitalonvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BAnimal-StrongDraft13/39 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
Epitalon
KPV
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
—
No melanocortin receptor binding
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
KPV
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
200–500 mcg / day SQ or oralDalle-Pang 2024
Frequency
Once daily during a cycle
Daily or 2–3× per week
Lower / starter dose
2.5 mg / day
100 mcg / day
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration
10–20 day cycles, 1–2× per year
4–8 weeks per cycle
Reconstitution
Bacteriostatic water
Bacteriostatic water (SQ form)
Timing
Pre-sleep preferred (pineal alignment)
No specific time; often taken with / before meals (oral)
Half-life
Hours (estimated)
Hours (estimated; rapid tissue uptake)
04Side Effects & Safety
Parameter
Epitalon
KPV
Injection site reaction
Mild irritation
Mild irritation
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
—
Long-term safety
Limited Western RCT data
Limited human data
Pregnancy / OB
Avoid
Avoid — insufficient data
Antibody formation
Not reported
—
GI symptoms
—
Rare nausea (oral form)
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
Epitalon
- ·Family history of cancer
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
Epitalon
KPV
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Pre-sleep preferred to align with pineal axis.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G insulin syringe (SQ form).
06Stack Synergy
Epitalon
— no documented stacks
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions